Table 2 Seropositive autoantibodies associated with patient membership in each cluster.

IL6R

36.33 (13.13–100.55)

4.59E–12

<1E–06

IL17RA

23.39 (9.53–57.39)

5.80E–12

<1E–06

CD86

19.21 (8.13–45.37)

1.58E–11

<1E–06

CSF2RA

20.08 (8.38–48.10)

1.71E–11

<1E–06

CD80

18.66 (7.87–44.21)

2.95E–11

<1E–06

CCL2

17.74 (7.52–41.86)

5.10E–11

<1E–06

TNFSF13

16.49 (7.04–38.59)

1.06E–10

<1E–06

CTSL^a

3.44 (1.58–7.50)

1.90E–03

0.023

TLR2^a

3.56 (1.51–8.38)

3.72E–03

0.037

IL15^a

3.18 (1.43–7.06)

4.44E–03

0.040

C4B^a

6.11 (2.35–15.92)

2.08E–04

0.019

CSF2RA

9.50 (4.44–20.34)

6.66E–09

1E–06

CD80

9.27 (4.34–19.79)

8.86E–09

1E–06

IL17RA

8.76 (4.17–18.41)

1.03E–08

1E–06

CCL2

8.96 (4.20–19.11)

1.41E–08

1E–06

TNFSF13

9.00 (4.14–19.56)

2.86E–08

1E–06

CD86

8.60 (4.00–18.50)

3.65E–08

1E–06

IL6R

6.99 (3.43–14.25)

8.87E–0

2E–06

VIM_c

3.78 (1.89–7.59)

1.78E–04

0.004

SPP1_c

3.23 (1.64–6.36)

6.91E–04

0.014

EIF4H_c

3.25 (1.55–6.82)

1.82E–03

0.033

CLU_c

2.78 (1.45–5.36)

2.20E–03

0.036

SPP1_c

20.48 (9.30–45.10)

6.37E–14

<1E–06

RBMS1_c^a

13.92 (6.97–27.80)

8.89E–14

<1E–06

VIM_c

30.17 (12.25–74.27)

1.25E–13

<1E–06

DNAJB1_c^a

12.83 (6.47–25.42)

2.60E–13

<1E–06

HNRNPA1_c^a

10.54 (5.55–20.02)

6.37E–13

<1E–06

FN1_c^a

10.23 (5.43–19.30)

6.58E–13

<1E–06

TRA2B_c^a

10.43 (5.36–20.29)

5.04E–12

<1E–06

CLU_c

9.29 (4.85–17.78)

1.69E–11

<1E–06

NONO_c^a

17.17 (7.28–40.57)

8.55E–11

<1E–06

SFPQ_c^a

6.92 (3.76–12.75)

5.35E–10

<1E–06

CPSF6_c^a

6.92 (3.76–12.75)

1.74E–09

<1E–06

TNC_c^a

5.99 (3.23–11.11)

1.36E–08

<1E–06

AEBP1_c^a

5.12 (2.76–9.52)

2.36E–07

3E–06

EIF4H_c

130.97 (17.44–983.47)

2.15E–06

2.8E–05

ASMTL_c^a

7.45 (10.59–581.40)

1.96E–05

2.37E–04

PDIA6_c^a

4.74 (2.29–9.80)

2.79E–05

3.16E–04

FGB_c^a

3.49 (1.92–6.34)

4.34E–05

4.62E–04

DDX5_c^a

3.79 (1.97–7.26)

6.14E–05

6.17E–04

ACTB_c^a

3.33 (1.63–6.82)

9.86E–04

0.001

SRSF7_c^a

2.94 (1.52–5.70)

1.35E–03

0.012